Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design

J Control Release. 2012 Mar 28;158(3):362-70. doi: 10.1016/j.jconrel.2011.10.009. Epub 2011 Oct 14.

Abstract

siRNA therapeutics are currently regarded as promising candidates to make a leap forward in the search for treatments of various hard to cure diseases. In order to exploit the full potential of siRNA based therapeutics, development of delivery systems that can efficiently guide the siRNA molecules to their target without major side effects will be the key to success. Lipid based delivery systems, originating from earlier research in the fields of gene delivery, are the most studied candidates for siRNA delivery. Here we discuss the requirements that need to be met by these siRNA delivery systems to ensure adequate stability after systemic application and subsequent deposition in the target tissue. The encountered hurdles in the blood stream and the solutions proposed in literature are discussed.

Publication types

  • Review

MeSH terms

  • Animals
  • Drug Carriers / administration & dosage*
  • Drug Carriers / chemistry
  • Drug Stability
  • Humans
  • Liposomes
  • RNA, Small Interfering / administration & dosage*
  • RNA, Small Interfering / chemistry

Substances

  • Drug Carriers
  • Liposomes
  • RNA, Small Interfering